China CAS:51333-22-3 Manufacturer

Our primary intention should be to offer our clientele a serious and responsible enterprise relationship, delivering personalized attention to all of them for CAS:51333-22-3, We're seeking forward to forming successful business enterprise romantic relationship with new shoppers in the around upcoming!
CAS:51333-22-3, With its rich manufacturing experience, high-quality products, and perfect after-sale service, the company has gained good reputation and has become one of the famous enterprise specialized in manufacturing series.We sincerely hope to establish business relation with you and pursue mutual benefit.

Hot Products

  • Tibolone

    Tibolone

    Tibolone complies with EP specification. DMF is approved.

    CAS:5630-53-5

  • Eplerenone

    Eplerenone

    Eplerenone has EP specifications. CEP available and FDA approved.

    CAS:107724-20-9

  • Eslicarbazepine Acetate

    Eslicarbazepine Acetate

    Eslicarbazepine Acetate has In-house specification. DMF approved.

    CAS:236395-14-5

  • Epiandrosterone

    Epiandrosterone

    Epiandrosterone is a steroid hormone with weak androgenic activity. It is a metabolite of testosterone and dihydrotestosterone (DHT).

    CAS:481-29-8

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • 4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic acid

    4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic acid

    4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic acid is an intermediate of Dutasteride.

    CAS:103335-55-3

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept